As of my knowledge cutoff date of September 2021, there were several Emergency Use Authorizations (EUA) issued by the U.S. Food and Drug Administration (FDA) for antibody treatments against COVID-19.
One such treatment is bamlanivimab, which is a monoclonal antibody therapy authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are at high risk of developing severe disease or requiring hospitalization. Another treatment is casirivimab/imdevimab, a combination therapy of two monoclonal antibodies that is authorized for the treatment of mild to moderate COVID-19 in adult and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19, including hospitalization or death.
It is important to note that the EUAs for these antibody treatments are subject to change as new information becomes available, and that patients should consult with their healthcare providers to determine the most appropriate treatment option for their individual circumstances.